Mycoplasma testing market to grow by USD 645.51 million from 2022 to 2027, North America to account for 40% of market growth- Technavio

NEW YORK, Sept. 19, 2023 /PRNewswire/ — The mycoplasma testing market size is expected to grow by USD 645.51 million from 2022 to 2027. In addition, the momentum of the market will be progressing at a CAGR of over 12.25% during the forecast period, according to Technavio Research. The market has been segmented by end-user (Pharmaceutical and biotechnology companies, Cell banks, Academic research institutes, CROs, and Others), product (Consumables and Systems), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to contribute 40% to the growth of the global market during the forecast period. One of the major factors significantly contributing to the growth of the market in North America is the increasing number of life sciences researchers and the presence of life science research companies and laboratories like the Charles River Laboratory and Gibraltar. Some of the main end users using mycoplasma testing to control mycoplasma contamination are biotechnology, biotech, and pharmaceutical companies. Furthermore, factors such as a growing focus on drug and vaccine discovery and development as well as the presence of several prominent market players in the region offering a wide range of mycoplasma testing products are driving market growth in the region during the forecast period. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read FREE PDF Sample Report

Company Profile:

Agilent Technologies Inc., ATCC, Akron Biotechnology LLC, Becton Dickinson and Co., Bio-Techne Corp., Bionique Testing Laboratories Inc., Charles River Laboratories International Inc., DiaSorin SpA, Dilarus GmbH, F. Hoffmann La Roche Ltd., GeneCopoeia Inc., InvivoGen Corp., Lonza Group Ltd., Merck KGaA, Norgen Biotek Corp., PromoCell GmbH, Sartorius AG, ScienCell Research Laboratories Inc., SGS SA, and Thermo Fisher Scientific Inc.

Agilent Technologies Inc: The company offers mycoplasma testing products such as MycoSensor qPCR assay kits.

To gain access to more company profiles available with Technavio, buy the report!

Mycoplasma Testing Market: Segmentation Analysis

The pharmaceutical and biotechnology companies segment is estimated to witness significant growth during the forecast period.

 Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report

“Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021”- Technavio

Mycoplasma Testing Market: Driver & Trend:

  • Rise in adoption of real-time mycoplasma testing
  • Increasing focus on R and D of biopharmaceuticals
  • Growing geriatric population

The rise in the adoption of real-time mycoplasma testing is the key factor driving the growth of the market.  One of the key benefits of real-time mycoplasma testing is that it can quickly detect the presence of mycoplasma contamination in biological products. In addition, a number of market participants are increasingly focused on developing real-time mycoplasma testing products. Besides, real-time mycoplasma testing products in cell lines, cell banks, pharmaceutical and biotech companies, CROs, research institutes, and harvesting vehicles are increasing in popularity, which is expected to drive the growth of the market during the forecast period.  

The increasing initiatives for rapid diagnostics of infectious diseases are the primary trend in the market.  Identify key trends, drivers, and challenges in the market. Download FREE sample to gain access to this information.


  • How do the major trends impact the market?
  • How big is the Nortth America market?
  • How do the key drivers and challenges impact the market?

Related Reports:

The cancer diagnostics market is estimated to grow at a CAGR of 11.3% between 2022 and 2027. The market size is forecast to increase by USD 12,626.21 million. Furthermore, this report extensively covers market segmentation by end-user (hospitals and clinics, and diagnostic laboratories), type (IVD, imaging, and IDT), and geography (North America, Europe, APAC, and the Rest of the World (ROW)). The high prevalence of cancer is a key factor driving market growth during the forecast period.

The Global Companion Diagnostics Market size is estimated to grow at a CAGR of 22.59% between 2022 and 2027. This companion diagnostics market report extensively covers market segmentation by end-user (life science, health centers, and others), indication (oncology, neurology, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. 

Table of Contents:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by End-user

7 Market Segmentation by Product 

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Company Landscape

12 Company Analysis

13 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]


SOURCE Technavio